Yogish C. Kudva MBBS

Dr. Yogish C. Kudva centers on improving existing treatments and developing novel therapies for patients with type 1 diabetes. In particular, Dr. Kudva is interested in developing an effective artificial pancreas system to improve outcomes for patients with type 1 diabetes. Additionally, his research contributes to the creation of new and better cell replacement therapies for patients with type 1 diabetes.

Dr. Kudva has played a key role in the development of the Diabetes Technology Clinic and program started in 2003 at Mayo Clinic's campus in Rochester, Minnesota. The infrastructure set up by this program resulted in NIH funding for further research in the field of closed-loop (artificial pancreas) therapy for type 1 diabetes. The program is now well-positioned to test the system for weeks to months in the years to come as part of national and international consortia. He works closely with Mayo's kidney and pancreas transplant surgical teams to continually improve the outcomes of these types of transplants. The transplant program provides long-term insulin independence for more than 60 percent of patients and freedom from hypoglycemia and ketoacidosis for more than 80 percent of patients. He collaborates with Mayo's gene therapy and regenerative medicine teams, led by Dr. Ikeda, to develop stem cell therapy for patients with type 1 diabetes.